Trial Profile
A study to evaluate the effects of ipilimumab on tumor-infiltrating T-cells in patients with stage IV malignant melanoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Sep 2015 New trial record